Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients
- 1 July 2016
- journal article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 22 (7) , 472-477
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBIThe International Journal of Tuberculosis and Lung Disease, 2015
- Hepatotoxicity mechanisms of isoniazid: A mini‐reviewJournal of Applied Toxicology, 2015
- Future of Pharmacogenetics-Based Therapy for TuberculosisPharmacogenomics, 2014
- Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-AnalysisPLOS ONE, 2012
- Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date reviewJournal of Gastroenterology and Hepatology, 2007
- An Official ATS Statement: Hepatotoxicity of Antituberculosis TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis InfectionChest, 2005
- Glutathione S-transferase: genetics and role in toxicologyToxicology Letters, 2000
- Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosisEuropean Respiratory Journal, 1996
- Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and RatScience, 1976